Edition:
United States

OpGen Inc (OPGN.OQ)

OPGN.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
4:00pm EDT
Change (% chg)

$-0.03 (-1.49%)
Prev Close
$2.01
Open
$2.03
Day's High
$2.03
Day's Low
$1.96
Volume
11,389
Avg. Vol
66,577
52-wk High
$10.47
52-wk Low
$1.62

Chart for

About

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening... (more)

Overall

Beta: --
Market Cap(Mil.): $12.46
Shares Outstanding(Mil.): 5.96
Dividend: --
Yield (%): --

Financials

  OPGN.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -4.71 -- --
ROI: -247.44 -3.67 13.17
ROE: -273.79 -5.61 15.10

BRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of Up To 2.7 Million Shares Of Common Stock

* OPGEN INC FILES PROSPECTUS SUPPLEMENT RELATING TO OFFERING OF UP TO 2.7 MILLION SHARES OF COMMON STOCK ISSSUABLE UPON EXERCISE OF WARRANTS - SEC FILING Source text - https://bit.ly/2KnXZt7 Further company coverage:

May 14 2018

BRIEF-Opgen Inc Files Prospectus Supplement Relating To Offering Of 1.05 mln Shares Of Co's Common Stock

* OPGEN INC FILES PROSPECTUS SUPPLEMENT RELATING TO OFFERING OF 1.05 MILLION SHARES OF CO'S COMMON STOCK ISSSUABLE UPON EXERCISE OF WARRANTS - SEC FILING Source text - (https://bit.ly/2InCHLp) Further company coverage:

May 14 2018

BRIEF-Opgen Reports Q1 Loss Per Share Of $0.75

* OPGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

May 08 2018

BRIEF-Opgen Reports Q4 Loss Per Share $1.33

* OPGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

Mar 15 2018

BRIEF-Opgen Says Collaborating With Beth Israel Deaconess Medical Center In Boston

* OPGEN ANNOUNCES COLLABORATOR IN VERIFICATION STUDY FOR ACUITAS® TEST

Mar 13 2018

BRIEF-OpGen Says ‍Entered Agreement To Use Thermo Fisher's Real-Time PCR Technology In Co's New Acuitas Tests​

* OPGEN INC - ‍ENTERED GLOBAL SUPPLY AGREEMENT TO USE THERMO FISHER SCIENTIFIC'S REAL-TIME PCR TECHNOLOGY IN COMPANY'S ACUITAS AMR GENE PANEL TESTS​

Feb 13 2018

BRIEF-Empery Asset Management Lp Reports 9.38 pct Passive Stake In Opgen Inc As Of Feb 1

* EMPERY ASSET MANAGEMENT, LP REPORTS 9.38 PERCENT PASSIVE STAKE IN OPGEN INC AS OF FEBRUARY 1, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2FUhgjF) Further company coverage:

Feb 08 2018

BRIEF-Opgen Regains Compliance With Nasdaq Listing Requirements

* OPGEN REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:

Feb 05 2018

Earnings vs. Estimates